Status:
COMPLETED
A Study of the Efficacy of RWJ-333369 in the Prevention of Migraine
Lead Sponsor:
SK Life Science, Inc.
Conditions:
Migraine Headaches
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate whether RWJ-333369 is a safe and effective treatment in reducing the number of migraine headaches when added to a person's usual medications for acute migraine...
Eligibility Criteria
Inclusion
- Established history of migraines for at least 1 year;
- Have between 3 and 12 migraine attacks per month, and no more than 15 headache days in total per month;
- Migraines must have first started before age 50.
Exclusion
- Most frequent headache type is not migraine;
- Failed 3 or more studies of effective migraine-preventing medications;
- Overuse of pain medications to treat migraines;
- Not willing to stop use of migraine-preventing medications;
- Significant serious concomitant diseases.
Key Trial Info
Start Date :
March 1 2002
Trial Type :
INTERVENTIONAL
End Date :
February 1 2006
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00109083
Start Date
March 1 2002
End Date
February 1 2006
Last Update
August 2 2012
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Northport, Alabama, United States
2
Phoenix, Arizona, United States
3
Little Rock, Arkansas, United States
4
Berkeley, California, United States